Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine whether consumption of Omega-3 supplement, at the defined dose, can reduce activated Nuclear Factor kappa B in peripheral blood lymphocytes from patients with MGUS and SMM and in malignant lymphocytes from patients with CLL.
Oscar F Ballester, MD
Marshall University/University Oncology Services at Edwards Comprehensive Cancer Center
United States: Institutional Review Board
|Edwards Comprehensive Cancer Center||Huntington, West Virginia 25701|